Heart drug vericiguat shows promise for ACS patients with low ejection fraction
NCT ID NCT06321094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the drug vericiguat can help people who have had a heart attack or unstable angina and also have a weak heart (ejection fraction below 45%). The main goal was to see if it lowers the chance of dying from heart problems or being hospitalized for heart failure. 149 adults took part, and researchers tracked heart function, a key blood marker, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Marathon runners and heart patients put a new troponin test to the ultimate challenge
- Bedside flu shot for heart patients: a simple strategy to save lives?
- Zapping lung nerves could ease heart Failure-Related high blood pressure
- Could a Two-Drug combo stop repeat heart attacks?
- Ear zaps during heart attack may shield the heart from damage
- Stiff arteries may hold key to heart failure progression